CXCR2 and neoplasm: To address these gaps, future investigations should prioritize validating N1/N2 TAN markers (e.g., CXCR2, PD-L1) in clinical cohorts using spatial transcriptomics to map miR-941’s spatial regulation within the tumor-stroma-neutrophil niche.